• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

What If AstraZeneca's Covid-19 Vaccine Doesn't Work?

Governments around the world have committed to buying hundreds of millions of doses of AZD1222.
By JIM COLLINS
Nov 27, 2020 | 10:30 AM EST
Stocks quotes in this article: AZN

Oh. My. God. Once again I am forced to quote John Hillerman's legendary character Jonathan Quayle Higgins from Magnum P.I. In this case I am delaying my Thanksgiving turkey to read the shocking news coming from AstraZeneca (AZN) re: its Covid-19 vaccine, which has been developed in partnership with Oxford University.

AstraZeneca's Covid-19 vaccine candidate AZD1222 produced decidedly mediocre results (62% efficacy) when given its intended, two-shot, equal-dose formulation. AstraZeneca researchers noticed that a cohort of the study group had mysteriously been given an incorrect dosing in the first round (50% of the planned level) and that that cohort performed significantly better (90% efficacy) than the group given the planned dosing. Astra's head of biopharmaceutical research, Dr. Mene Pangalos, attributed this result, in an interview with the Daily Mail, to "serendipity."

This is a joke. It has nothing to do with science. Serendipity? Are you kidding me? We are going to fight the greatest pandemic to hit the world in 102 years with serendipity? Come on.

As much as I love the Daily Mail, I felt compelled, as always, to go to Astra's actual release on the preliminary results from its trial. While Astra noted "no hospitalizations or serious cases" of Covid-19 among its trial groups, it did note 131 subjects had tested positive among a total study cohort of 11,636. The testing group caught Covid-19 at a rate of slightly more than 1%, and with 60 million cases globally now, according to Johns Hopkins data, AZN's Covid infection rate would appear to be slightly above the rate at which Covid-19 infections impact the general public. Also, the incorrectly given dosing cohort (n=2,741) was much smaller than those given the proper double full dose (n=8,895), so sample size and data sufficiency have to be an issue here.

To that end, AZN's CEO Pascal Soriot mentioned in interviews yesterday the need for additional testing. That's where this story becomes interesting to me as a trader. This is when my brain starts percolating and I start to think, "how can I short this thing? "

The first thing to remember is that AstraZeneca stock has already performed poorly. Even before yesterday's mild decline in London trading (it's not Thanksgiving there, so markets were open), AstraZeneca shares had been a major laggard both on London and New York bourses in recent trading. In the past six months, a period that began after the Covid-19 crash had already begun to reverse, Astra shares have been flat in New York and fallen about 10% in London. In contrast, the main benchmarks have shot up, with the FTSE 100 rising about 3% in the past six months and the S&P 500, driven by the red-hot Nasdaq, rising about 18% in that period..

So AstraZeneca has been a poor performer on a relative basis, but what I am looking for here is some serious absolute underperformance, i.e. the stock goes down a lot. Astra is down again today in London trading (off about 1%,) and AZN shares touched a low of $36.14 during the March Covid-19 crash. Though I am no technician, I could see AZN shares reaching that level again if additional data from AZD1222 does not reflect "serendipity."

AstraZeneca has made a "no profit" pledge on its Covid-19 vaccine. Kumbaya! While a "woke" pharma company is probably as attractive as a ''woke" oil company, the real issue for AZN is if "no profit" becomes "no efficacy." Governments around the world have committed to buying hundreds of millions of doses of AZD1222, and AstraZeneca's release noted that the company planned to have the capacity to produce 3.1 billion doses by the end of 2021.

So what if it doesn't work? Hey, that's just serendipity.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jim Collins had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Healthcare | Pharmaceuticals | Coronavirus

More from Investing

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

I See a Way to Make Some Bread Off of Toast Inc.

Bret Jensen
May 28, 2023 7:00 AM EDT

Here's an options play on this software company for the restaurant industry.

Don't Just Sit There and 'Hope' for Your Stocks, Make a Decision

James "Rev Shark" DePorre
May 27, 2023 10:00 AM EDT

The biggest investing and trading mistake that people make is that they don't have a plan.

3 High-Yield International Oil & Gas Majors

Bob Ciura
May 27, 2023 7:15 AM EDT

The top global energy names are returning more cash to shareholders through dividends and share repurchases.

Nvidia Caught Traders Off Guard, Will Debt News Do the Same Soon?

James "Rev Shark" DePorre
May 26, 2023 4:57 PM EDT

We got a broad rally on Friday after a week of narrow action -- but once the debt ceiling news hits, the market will go on to the next stage of action.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login